A61K 47/6825
Ribosomal inhibitory proteins, i.e. rip-i or rip-ii
Official title: {Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin}
A61K47/6825 (Ribosomal inhibitory proteins, i.e. rip-i or rip-ii) appears on 205 US grants and 235 published applications in this corpus.
Search patents in A61K- Granted patents
- 205
- Published applications
- 235
- Assignees
- 132
- Inventors
- 428
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 3 | 0 |
| 1983 | 2 | 0 |
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 1 | 0 |
| 1987 | 4 | 0 |
| 1988 | 2 | 0 |
| 1989 | 3 | 0 |
| 1990 | 9 | 0 |
| 1991 | 2 | 0 |
| 1992 | 3 | 0 |
| 1993 | 1 | 0 |
| 1994 | 2 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 7 | 0 |
| 1998 | 5 | 0 |
| 1999 | 6 | 0 |
| 2000 | 7 | 0 |
| 2001 | 2 | 0 |
| 2002 | 6 | 5 |
| 2003 | 4 | 6 |
| 2004 | 2 | 5 |
| 2005 | 1 | 5 |
| 2006 | 6 | 10 |
| 2007 | 3 | 3 |
| 2008 | 3 | 5 |
| 2009 | 2 | 6 |
| 2010 | 6 | 11 |
| 2011 | 3 | 11 |
| 2012 | 8 | 4 |
| 2013 | 6 | 12 |
| 2014 | 2 | 11 |
| 2015 | 14 | 7 |
| 2016 | 12 | 17 |
| 2017 | 11 | 18 |
| 2018 | 12 | 7 |
| 2019 | 3 | 11 |
| 2020 | 7 | 16 |
| 2021 | 7 | 9 |
| 2022 | 6 | 10 |
| 2023 | 6 | 20 |
| 2024 | 2 | 10 |
| 2025 | 4 | 12 |
| 2026 | 5 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Semicarbazone-based saponin conjugate18 Aug 2026US 12,708,638 B2Sapreme Technologies B.V.
- Diagnosis and treatment of cancer28 Jul 2026US 12,693,294 B2Rab Diagnostics AS
- Binding molecules specific for CD73 and uses thereof19 May 2026US 12,630,648 B2Medlmmune, LLC
- Photosensitizing dye14 Apr 2026US 12,600,734 B2PhotoQ3 Inc.
- Electroporation-targeted delivery of ribosome inactivating protein gelonin into mammalian cells10 Feb 2026US 12,544,420 B2Old Dominion University Research Foundation
- Immunotoxins, formulations thereof and their use in medicine3 Sep 2026US 2026/0258129 A1Philikos B.V.
- Binding molecules specific for cd73 and uses thereof27 Aug 2026US 2026/0250424 A1MedImmune, LLC
- Compositions and methods for the treatment and diagnosis of cancers associated with surface k-ras11 Jun 2026US 2026/0158070 A1University of Maryland, Baltimore
- Antibody-drug conjugate with improved therapeutic window1 Jan 2026US 2026/0000783 A1Sapreme Technologies B.V.
- Recombinant immunotoxin comprising a ribosome inactivating protein25 Dec 2025US 2025/0387478 A1
Most cited
By later US patents
- Human monoclonal antibodies to programmed death ligand 1 (PD-L1)628US 7,943,743 B2Medarex, Inc. · 2011
- Solubilization of proteins for pharmaceutical compositions using polymer conjugation538US 4,766,106 ACetus Corporation · 1988
- Recombinant production of immunoglobulin-like domains in prokaryotic cells477US 6,165,745 ABoard of Regents, The University of Texas System · 2000
- Interleukin-2 muteins and polymer conjugation thereof444US 5,206,344 ACetus Oncology Corporation · 1993
- Compositions for targeting the vasculature of solid tumors254US 6,051,230 ABoard of Regents, The University of Texas System · 2000